Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations

Gabriella Gamba, Guido Grignani, Vincenzo Montera, Gianna Perotti, Livio Ragone, Edoardo Ascari

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In patients with maturity-onset diabetes mellitus without thromboembolic manifestations, significant increases in both fibrinolytic and antifibrinolytic activity were demonstrated. The increased fibrinolytic activity observed under basal conditions could be due to the continuous release of plasminogen activators from damaged endothelial cells. This hypothesis is supported by the fact that the higher fibrinolytic activity observed in diabetics is followed by a lesser increase in fibrinolytic activity than in controls after the venous occlusion test. The main antiplasmins, except α2-antiplasmin, were significantly higher in diabetics, and their levels were not affected by sex, metabolic regulation, retinopathy, duration of the disease or cholesterolemia. On the contrary, weight, therapy and triglyceridemia significantly influenced the levels of some anti-plasmins. Furthermore, hypertriglyceridemia and hypercholesterolemia were associated with a reduction of fibrinolysis. Thus, these conditions may further increase the risk of thromboembolic complications of diabetes mellitus.

Original languageEnglish
Pages (from-to)337-347
Number of pages11
JournalLa Ricerca in Clinica e in Laboratorio
Volume13
Issue number3
DOIs
Publication statusPublished - Jul 1983

Fingerprint

Antifibrinolytic Agents
Medical problems
Type 2 Diabetes Mellitus
Hypertriglyceridemia
Plasminogen Activators
Fibrinolysin
Endothelial cells
Fibrinolysis
Diabetes Complications
Hypercholesterolemia
Endothelial Cells
Weights and Measures
Therapeutics

Keywords

  • Diabetes mellitus
  • Fibrinolysis inhibitors
  • Fibrinolytic activity
  • Thromboembolic manifestations

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations. / Gamba, Gabriella; Grignani, Guido; Montera, Vincenzo; Perotti, Gianna; Ragone, Livio; Ascari, Edoardo.

In: La Ricerca in Clinica e in Laboratorio, Vol. 13, No. 3, 07.1983, p. 337-347.

Research output: Contribution to journalArticle

Gamba, Gabriella ; Grignani, Guido ; Montera, Vincenzo ; Perotti, Gianna ; Ragone, Livio ; Ascari, Edoardo. / Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations. In: La Ricerca in Clinica e in Laboratorio. 1983 ; Vol. 13, No. 3. pp. 337-347.
@article{67cd26bb08bd4e70ad4ceee7e581b9d9,
title = "Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations",
abstract = "In patients with maturity-onset diabetes mellitus without thromboembolic manifestations, significant increases in both fibrinolytic and antifibrinolytic activity were demonstrated. The increased fibrinolytic activity observed under basal conditions could be due to the continuous release of plasminogen activators from damaged endothelial cells. This hypothesis is supported by the fact that the higher fibrinolytic activity observed in diabetics is followed by a lesser increase in fibrinolytic activity than in controls after the venous occlusion test. The main antiplasmins, except α2-antiplasmin, were significantly higher in diabetics, and their levels were not affected by sex, metabolic regulation, retinopathy, duration of the disease or cholesterolemia. On the contrary, weight, therapy and triglyceridemia significantly influenced the levels of some anti-plasmins. Furthermore, hypertriglyceridemia and hypercholesterolemia were associated with a reduction of fibrinolysis. Thus, these conditions may further increase the risk of thromboembolic complications of diabetes mellitus.",
keywords = "Diabetes mellitus, Fibrinolysis inhibitors, Fibrinolytic activity, Thromboembolic manifestations",
author = "Gabriella Gamba and Guido Grignani and Vincenzo Montera and Gianna Perotti and Livio Ragone and Edoardo Ascari",
year = "1983",
month = "7",
doi = "10.1007/BF02905877",
language = "English",
volume = "13",
pages = "337--347",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic manifestations

AU - Gamba, Gabriella

AU - Grignani, Guido

AU - Montera, Vincenzo

AU - Perotti, Gianna

AU - Ragone, Livio

AU - Ascari, Edoardo

PY - 1983/7

Y1 - 1983/7

N2 - In patients with maturity-onset diabetes mellitus without thromboembolic manifestations, significant increases in both fibrinolytic and antifibrinolytic activity were demonstrated. The increased fibrinolytic activity observed under basal conditions could be due to the continuous release of plasminogen activators from damaged endothelial cells. This hypothesis is supported by the fact that the higher fibrinolytic activity observed in diabetics is followed by a lesser increase in fibrinolytic activity than in controls after the venous occlusion test. The main antiplasmins, except α2-antiplasmin, were significantly higher in diabetics, and their levels were not affected by sex, metabolic regulation, retinopathy, duration of the disease or cholesterolemia. On the contrary, weight, therapy and triglyceridemia significantly influenced the levels of some anti-plasmins. Furthermore, hypertriglyceridemia and hypercholesterolemia were associated with a reduction of fibrinolysis. Thus, these conditions may further increase the risk of thromboembolic complications of diabetes mellitus.

AB - In patients with maturity-onset diabetes mellitus without thromboembolic manifestations, significant increases in both fibrinolytic and antifibrinolytic activity were demonstrated. The increased fibrinolytic activity observed under basal conditions could be due to the continuous release of plasminogen activators from damaged endothelial cells. This hypothesis is supported by the fact that the higher fibrinolytic activity observed in diabetics is followed by a lesser increase in fibrinolytic activity than in controls after the venous occlusion test. The main antiplasmins, except α2-antiplasmin, were significantly higher in diabetics, and their levels were not affected by sex, metabolic regulation, retinopathy, duration of the disease or cholesterolemia. On the contrary, weight, therapy and triglyceridemia significantly influenced the levels of some anti-plasmins. Furthermore, hypertriglyceridemia and hypercholesterolemia were associated with a reduction of fibrinolysis. Thus, these conditions may further increase the risk of thromboembolic complications of diabetes mellitus.

KW - Diabetes mellitus

KW - Fibrinolysis inhibitors

KW - Fibrinolytic activity

KW - Thromboembolic manifestations

UR - http://www.scopus.com/inward/record.url?scp=0020786217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020786217&partnerID=8YFLogxK

U2 - 10.1007/BF02905877

DO - 10.1007/BF02905877

M3 - Article

VL - 13

SP - 337

EP - 347

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 3

ER -